Physician profile
Emily Johnston
NPI 1053794263
$2,839.48
in general payments reported to CMS, 2019-2025
24 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $701 · 2022: $387 · 2023: $809 · 2024: $488 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,750.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $719.68 | 2021-2024 | Rayaldee |
| Boston Scientific Corporation | $316.27 | 2023 | |
| Daiichi Sankyo INC. | $186.21 | 2021-2025 | Injectafer |
| Travere Therapeutics, INC. | $181.76 | 2022-2025 | |
| Vifor Pharma, INC. | $169.45 | 2022-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $159.86 | 2023-2025 | |
| Amgen INC. | $154.10 | 2025 | Tavneos, Krystexxa |
| Akebia Therapeutics INC | $143.47 | 2021-2025 | Vafseo |
| Nxstage Medical, INC. | $101.21 | 2021-2025 | Nxstage System One |
| Astrazeneca Pharmaceuticals LP | $97.86 | 2021-2025 | Lokelma, Farxiga |
| Calliditas Therapeutics US INC. | $97.21 | 2023-2025 | Tarpeyo |
| Argenx US, INC. | $87.88 | 2024 | Vyvgart |
| Ardelyx, INC. | $85.25 | 2024 | Xphozah 30 Mg |
| Glaxosmithkline, LLC. | $84.15 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.16 | 2024-2025 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $31.44 | 2023 | |
| Ani Pharmaceuticals, INC. | $29.25 | 2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $26.99 | 2021 | |
| Pharmacosmos Therapeutics INC. | $24.22 | 2024 | Monoferric |
| Apellis Pharmaceuticals, INC. | $20.18 | 2025 | Empaveli |
| Amicus Therapeutics, INC. | $18.98 | 2021 | |
| Mallinckrodt Hospital Products INC. | $18.34 | 2025 | Terlivaz |
| Fresenius USA Marketing, INC. | $13.88 | 2024 | Velphoro |
| Alexion Pharmaceuticals, INC. | $13.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.